C5 and amyotrophic lateral sclerosis: Inhibition or ablation of C5a–C5aR1 activity has also been demonstrated to increase survival and lower motor deficits in models of amyotrophic lateral sclerosis (ALS) [10, 11], reduce seizure susceptibility and inflammation in experimental epilepsy [12, 13], and accelerate functional recovery after spinal cord injury [14].